Rubicon Research Limited Announces Postal Ballot for Independent Director and Secretarial Auditor Appointments

Rubicon Research Limited has announced a postal ballot process to seek shareholder approval for two significant appointments, as communicated to BSE Limited and National Stock Exchange of India Limited on February 13, 2026. Proposed Resolutions The company has outlined two key resolutions for shareholder consideration: Resolution No. Proposed Resolution Type 1 To appoint Dr. Pradnya Saravade (DIN: 08472973) as an Independent Woman Director Special Resolution 2 To appoint M/s. BNP & Associates, Company Secretaries, as the Secretarial Auditors Ordinary Resolution E-Voting Schedule The postal ballot will be conducted exclusively through remote e-voting, with the following timeline: Parameter Details Cut-off Date Friday, February 06, 2026 E-voting Commencement Saturday, February 14, 2026 at 9:00 A.M. (IST) E-voting End Sunday, March 15, 2026 at 5:00 P.M. (IST) Results Declaration On or before Tuesday, March 17, 2026 Independent Director Appointment Dr. Pradnya Saravade, a former Indian Police Service officer with extensive governance experience, has been proposed for appointment as an Independent Woman Director. Her appointment would be effective from February 03, 2026, to February 02, 2029, for a term of three consecutive years. Dr. Saravade brings significant expertise in: Strategic leadership and sector expertise Governance and risk management Ethics management Stakeholder relations and grievance redressal ESG and social impact initiatives People management Her professional background includes leadership roles at Maharashtra Railway Police, Securities and Exchange Board of India (SEBI), Central Bureau of Investigation (CBI), and Mumbai Police. She holds MBBS and MS (General Surgery) degrees from Grant Medical College, Mumbai. Secretarial Auditor Appointment M/s. BNP & Associates, Company Secretaries, has been recommended for appointment as the company's Secretarial Auditors for the financial year 2025-26. The firm holds Firm Registration Number P2014MH037400 and Peer Review No. 7353/2025. The appointment details include: Aspect Details Firm Registration P2014MH037400 Peer Review Number 7353/2025 Remuneration for FY 2025-26 ₹3,75,000 plus applicable taxes Scope Secretarial audit and compliance requirements Voting Process In compliance with Ministry of Corporate Affairs circulars, the postal ballot notice is being sent electronically to shareholders whose email addresses are registered with the company's Registrar and Share Transfer Agent, MUFG Intime India Private Limited, and the depositories NSDL and CDSL. Shareholders can access the e-voting facility through multiple channels: Company website: www.rubicon.co.in MUFG Intime platform: https://instavote.linkintime.co.in Stock exchange websites (BSE and NSE) Depository websites (NSDL and CDSL) The company has appointed Mr. Gaurav Sainani and Mr. Sunny Gogiya, Partners at M/s. S/GGS and Associates, Company Secretaries, as Scrutinizers for the postal ballot process. The voting rights of members will be proportionate to their shareholding in the paid-up equity share capital as on the cut-off date. Rubicon Research Limited has submitted its Q3 FY26 earnings conference call transcript to stock exchanges, revealing strong financial performance and management's optimistic outlook for future growth. Strong Q3 FY26 Financial Performance The company delivered robust financial results for the quarter ended December 31, 2025, with significant year-over-year improvements across key metrics. Financial Metric: Q3 FY26 Q3 FY25 Growth (%) Revenue from Operations: ₹476 crores ₹313 crores +52% EBITDA: ₹112 crores ₹70 crores +59% Net Profit: ₹73 crores ₹38 crores +91% EPS: ₹4.41 ₹2.31 +91% Operating EBITDA Margin: 22.7% 20.5% +220 bps Nine-Month Performance Highlights For the nine months ended December 31, 2025, the company maintained strong momentum with revenue reaching ₹1,240 crores, up 34% year-over-year. Nine-Month Metrics: FY26 (9M) FY25 (9M) Growth (%) Revenue: ₹1,240 crores ₹925 crores +34% Gross Profit: ₹833 crores ₹645 crores +29% Operating EBITDA: ₹282 crores ₹192 crores +47% Net Profit: ₹170 crores ₹98 crores +73% EPS: ₹10.67 ₹5.96 +79% R&D Investment and Future Growth Strategy CEO Parag Sancheti emphasized the company's strong R&D-driven growth model during the February 3, 2026 earnings call. The company maintained R&D expenses at ₹52 crores for the quarter, representing 11% of revenue, in line with guidance of 10%-11%. Sagar Oak, Senior Vice President of Corporate Development and Strategy, presented compelling data showing improving R&D productivity. The analysis revealed that R&D investment returns have increased from 3.3x to 5.7x over rolling three-year periods, demonstrating enhanced efficiency in product development and commercialization. Pithampur Facility Expansion The company is progressing with operationalizing its newly acquired Pithampur manufacturing facility, expected to be validated by mid-2026 with commercialization beginning in Q1 CY'27. This facility will provide capabilities for high potent oncology, hormones, and steroids production. Pithampur Facility Details: Timeline Facility Handover: June 2025 Validation Completion: Mid-2026 Commercial Production: Q1 CY'27 Investment: ₹149 crores Specialty Products Growth The specialty portfolio continues to strengthen, contributing 31%-32% of gross profit in Q2 and Q3, higher than the 26.9% contribution in full year FY25. Management highlighted successful launches including Fluticasone, where the company became the third to receive approval since 2007. Management Guidance and Outlook CFO Nitin Jajodia reaffirmed the company's commitment to maintaining operating EBITDA margins in the 22%-23% range despite temporary gross margin pressure from increased outsourcing to meet higher-than-expected demand. The company expects to invest over ₹500 crores in R&D across fiscals 2026, 2027, and Q1 2028, supporting continued revenue growth visibility through FY30. The earnings call transcript was submitted to BSE and NSE on February 6, 2026, by Company Secretary Deepakshree Tanksale, maintaining regulatory compliance under SEBI listing requirements. We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better. Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians. As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.